Novavax, Inc.
Every calculator, already run for NVAX
Open the full toolkit →You have the numbers on NVAX. Get the argument.
A written report on which of these readings actually decide the outcome for Novavax, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
9 analysts covering NVAXAnalyst Price Target Disagreement for Novavax, Inc.
Wall Street's bull case implies +147% from the current price; the bear case implies -31%. A 178% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for NVAX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Novavax, Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVAX — frequently asked
Is NVAX a buy right now?
Wall Street's consensus rating on Novavax, Inc. is Buy across 9 analysts, with a mean price target of $14.00 (+38% vs. the current $10.11). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is NVAX overvalued?
NVAX trades at — trailing earnings, against a DCF fair value of $10 per share. The current price implies 7% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is NVAX's next earnings date?
Novavax, Inc. is next scheduled to report earnings around Nov 5, 2026. A full NVAX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Novavax, Inc.?
Analysts covering Novavax, Inc. (NVAX) range from a bear-case target of $7.00 to a bull-case high of $25.00, with a mean consensus target of $14.00 across 9 analysts. The spread of $18.00 (178% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Novavax, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Novavax, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full NVAX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Novavax, Inc., in minutes. 3 free reports included with every account — no credit card required.